Compound Summary
oxaprozin
Compound Information
oxaprozin
Compound Name: | oxaprozin |
Compound CID: | 4614 |
Synonyms: | oxaprozin 21256-18-8 Daypro 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid Alvo More... |
Iupac Name: | 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid |
InChI: | InChI=1S/C18H15NO3/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14/h1-10H,11-12H2,(H,20,21) |
InChIKey: | OFPXSFXSNFPTHF-UHFFFAOYSA-N |
Canonical Smiles: | C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3 |
Isomeric Smiles: | C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3 |
Molecular Weight: | 293.3 |
Molecular Formula: | C18H15NO3 |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
oxaprozin
Molecular Weight: | 293.3 |
Molecular Formula: | C18H15NO3 |
Hydrogen Bond Donor Count: | 1 |
Hydrogen Bond Acceptor Count: | 4 |
Rotatable Bond Count: | 5 |
Heavy Atom Count: | 22 |
Complexity: | 361 |
Synonyms
oxaprozin
| oxaprozin | oxaprozin |
|---|---|
oxaprozin |
21256-18-8 |
Daypro |
3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid |
Alvo |
3-(4,5-Diphenyloxazol-2-yl)propanoic acid |
Oxaprozine |
Oxaprozinum |
Deflam |
Oxaprozine INN-French |
Oxaprozinum INN-Latin |
Oxaprozina INN-Spanish |
Oxaprozina |
WY-21,743 |
4,5-Diphenyl-2-oxazolepropionic acid |
WY-21743 |
4,5-Diphenyl-2-oxazolepropanoic acid |
Duraprox |
Oxaprozinum;Wy21743 |
2-Oxazolepropanoic acid, 4,5-diphenyl- |
WY 21743 |
NSC310839 |
3-(4,5-Diphenyl-2-oxazolyl)propenoic acid |
3-(diphenyl-1,3-oxazol-2-yl)propanoic acid |
beta-(4,5-Diphenyloxazol-2-yl)propionic acid |
UNII-MHJ80W9LRB |
MFCD00215977 |
MHJ80W9LRB |
NSC 310839 |
NSC-310839 |
CHEMBL1071 |
CHEBI:7822 |
Voir |
2-OXAZOLEPROPIONIC ACID, 4,5-DIPHENYL- |
.beta.-(4,5-Diphenyloxazol-2-yl)propionic acid |
Danoprox |
Dayrun |
3-(4,5-Diphenyl-2-oxazolyl)propanoic acid |
CAS-21256-18-8 |
DSSTox_CID_25118 |
DSSTox_RID_80684 |
DSSTox_GSID_45118 |
Actirin |
Xopane |
SMR000058286 |
Daypro (TN) |
SR-01000076053 |
oxaprosin |
Durapro |
Duraprost |
Oxaprozi |
Oxapro |
Walix |
Oxaprozin, solid |
Oxaprozin,(S) |
Oxaprozin- Bio-X |
EINECS 244-296-1 |
NCI310839 |
4, 5-Diphenyl-2-oxazolepropionic acid |
BRN 1083168 |
Maybridge1_008800 |
Prestwick0_001060 |
Prestwick1_001060 |
Prestwick2_001060 |
Prestwick3_001060 |
Spectrum2_001696 |
Spectrum3_001078 |
Spectrum4_001231 |
Lopac-O-9637 |
O 9637 |
SCHEMBL3286 |
NCIStruc1_000799 |
NCIStruc2_000787 |
BIDD:PXR0149 |
Lopac0_000944 |
Oprea1_509470 |
BSPBio_001020 |
BSPBio_002696 |
KBioGR_001722 |
MLS000759535 |
MLS001424072 |
BIDD:GT0438 |
SPECTRUM1505267 |
SPBio_001652 |
SPBio_002940 |
Oxaprozin (JP17/USP/INN) |
BPBio1_001122 |
GTPL7252 |
DTXSID1045118 |
HMS566H22 |
HSDB 7586 |
KBio3_001916 |
HMS1571C22 |
HMS1922P17 |
HMS2051L15 |
HMS2093O08 |
HMS2098C22 |
HMS3262N10 |
HMS3393L15 |
HMS3652H17 |
HMS3715C22 |
HMS3885L11 |
Pharmakon1600-01505267 |
Wy21743 |
AMY32551 |
BCP28431 |
HY-B0808 |
Tox21_110059 |
Tox21_500944 |
2-Oxazolepropanoic acid,5-diphenyl- |
2-Oxazolepropionic acid,5-diphenyl- |
BDBM50002861 |
CCG-36508 |
NCGC00014711 |
NSC758949 |
s4230 |
SBB053166 |
ZINC49643479 |
4,5-diphenyloxazole-2-propanoic acid |
4,5-Diphenyloxazole-2-propionic acid |
AKOS000206807 |
Oxaprozin USAN:USP:INN:BAN:JAN |
Tox21_110059_1 |
CS-7975 |
DB00991 |
KS-5196 |
LP00944 |
MCULE-7099031811 |
NC00214 |
NSC-758949 |
SDCCGSBI-0050918.P004 |
NCGC00014711-01 |
NCGC00014711-02 |
NCGC00014711-03 |
NCGC00014711-04 |
NCGC00014711-05 |
NCGC00014711-06 |
NCGC00014711-07 |
NCGC00014711-08 |
NCGC00014711-09 |
NCGC00014711-10 |
NCGC00014711-11 |
NCGC00014711-14 |
NCGC00014711-15 |
NCGC00094249-01 |
NCGC00094249-02 |
NCGC00094249-03 |
NCGC00094249-04 |
NCGC00094249-05 |
NCGC00094249-06 |
NCGC00094249-07 |
NCGC00261629-01 |
Oxaprozin 100 microg/mL in Acetonitrile |
AC-26512 |
BO164184 |
NCI60_002681 |
SBI-0050918.P002 |
AB0011812 |
3-(4,5-Diphenyl-2-oxazolyl)propionic acid |
AB00514024 |
B1804 |
EU-0100944 |
FT-0638104 |
O0377 |
ST50949623 |
SW197319-4 |
3-(4, 5-Diphenyl-2-oxazolyl)propenoic acid |
EN300-25629 |
3-(4,5-Diphenyl-oxazol-2-yl)-propionic acid |
4.5-Diphenyl-2-oxazolepropanoic acid|||Daypro |
C07356 |
D00463 |
J10396 |
AB00514024_08 |
AB00514024_09 |
256O188 |
A815225 |
1-AMINOCYCLOBUTANE-CIS-1,3-DICARBOXYLICACID |
J-013955 |
Q1749609 |
SR-01000076053-1 |
SR-01000076053-3 |
SR-01000076053-7 |
SR-01000076053-9 |
3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid # |
BRD-K25394294-001-05-7 |
BRD-K25394294-001-08-1 |
Z217102860 |
Oxaprozin, United States Pharmacopeia (USP) Reference Standard |
Experimental Data
oxaprozin
| Species | Dose | Unit | Control(Avg days) | Treatment(Avg days) | Avg/Med Lifespan Change(%) | Control(Max days) | Treatment(Max days) | Max Lifespan Change(%) | Significant | Strain | Gender | PubMed | Avg/Med Lifespan Change tab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 33.000000000000000 | umol/L | -5.000000000000000 | NS | N2 | 24134630 | Inactive |
Experimental Data Visualization
oxaprozin
Statistics Data
oxaprozin
| Species | Avg/Med Lifespan Change(%) | Max Lifespan Change(%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | -5.000000000000000 | 1 | 1 |
Statistics Data Visualization
oxaprozin
